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MesenchymalMenin plays an established role in the differentiation of mesenchymal cells to the osteogenic lineage.
Conversely, whether Menin inﬂuences the commitment of mesenschymal cells to the myogenic lineage,
despite expression in the developing somite was previously unclear. We observed that Menin is down-
regulated in C2C12 and C3H10T1/2 mesenchymal cells when muscle differentiation is induced. Moreover,
maintenance of Menin expression by constitutive ectopic expression inhibited muscle cell differentiation.
Reduction of Menin expression by siRNA technology results in precocious muscle differentiation and
concomitantly attenuates BMP-2 induced osteogenesis. Reduced Menin expression antagonizes BMP-2 and
TGF-β1 mediated inhibition of myogenesis. Furthermore, Menin was found to directly interact with and
potentiate the transactivation properties of Smad3 in response to TGF-β1. Finally in concert with these
observations, tissue-speciﬁc inactivation of Men1 in Pax3-expressing somite precursor cells leads to a
patterning defect of rib formation and increased muscle mass in the intercostal region. These data invoke a
pivotal role for Menin in the competence of mesenchymal cells to respond to TGF-β1 and BMP-2 signals.
Thus, by modulating cytokine responsiveness Menin functions to alter the balance of multipotent
mesenchymal cell commitment to the osteogenic or myogenic lineages.© 2009 Elsevier Inc. All rights reserved.IntroductionMesenchymal stem cells exist in a multipotent state until they
commit to various cell lineages such as osteogenic and myogenic cell
types. During ontogeny, differentiation of mesenchymal cells is
regulated by integrated signaling networks which orchestrate changes
in gene expression proﬁles leading to commitment to speciﬁc cell
lineages (Asakura et al., 2001; Brand-Saberi et al., 1996). Myogenesis,
the genetic process underlying the formation of multi-nucleated
skeletal muscle cells (myotubes, MT) is a proven paradigm for cellular
differentiation. Induction of the program for myogenic gene expres-
sion is critically dependent on transcription factors of the muscle
regulatory factor family (MRFs) which is comprised of, MyoD, Myf5,
MRF4 and Myogenin. The MRFs are members of the basic helix–loop–
helix (bHLH) family of transcription factors, which integrate with
ubiquitous transcription factors at the control regions of muscle-
speciﬁc genes to promote myogenesis (Buckingham, 1992; Emerson,
1993; Lassar et al., 1994; Olson and Klein, 1994). Several myogenicMuscle creatine kinase; MyHC,
scription factor; ALP, Alkaline
mbryonic day; MB, myoblast;
ia; DM, differentiation media;
).
l rights reserved.genomic loci that have been well characterised in terms of their
transcriptional circuitry, such as themuscle creatine kinase (MCK) and
myosin heavy chain (MyHC) genes, serve as useful models to study the
activation of tissue-speciﬁc gene expression during muscle differ-
entiation (Jaynes et al., 1986; Sacks et al., 2003).
Osteogenic differentiation parallels myogenesis as it requires
regulatory control of osteoblast-speciﬁc transcription factors such as
the runt-related transcription factor Runx2/Cbfa1 (Runx2) and
Osterix (Osx). The integration of pro-osteogenic transcription factors
such as Runx2 with ubiquitous transcription factors and signaling
pathway effectors regulates expression of osteoblast-speciﬁc genes
such as alkaline phosphatase (ALP) and osteocalcin (OCN) (Komori
et al., 1997; Nakashima et al., 2002; Otto et al., 1997). Thus, osteogenic
and myogenic commitment of mesenchymal cells provides a useful
system to study the commitment of multipotent progenitor cells into
different cell lineages.
The interplay between extracellular signals and transcriptional
regulation is a crucial nexus of control for cell lineage determination.
Members of the transforming growth factor (TGF-β) superfamily of
cytokines, including bone morphogenic protein-2 (BMP-2) and TGF-
β1, play important roles during osteogenesis andmyogenesis (Katagiri
et al., 1990, 1994, 1997; Liu et al., 2001; Massague et al., 1986;
Yamaguchi et al., 1991). Thus, competence to respond to the milieu of
local growth factors is a fundamental determinant of the eventual fate
of multipotent cells.
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TGF-β ligands, is most commonly regulated by ligand interaction
with a transmembrane serine/threonine kinase receptor complex,
resulting in phosphorylation-dependent activation of receptor-regu-
lated Smads (R-Smads). The BMP regulated R-Smads are Smad1, -5,
and -8; TGF-β regulated R-Smads are Smad2 and -3. Activated R-
Smads interact with the common Smad (C-Smad), Smad4, and this
complex translocates to the nucleus to regulate gene expression
(Massague and Wotton, 2000). In addition to regulation of gene
expression by co-operation with Smad4, R-Smads are implicated in
the regulatory control of other key transcription factors such as,
MyoD in muscle, and Runx2 in bone, during the regulation of
lineage-speciﬁc gene expression (Lee et al., 2000; Liu et al., 2001).
Thus, molecular integrators of these signals may be pivotal in
mesenchymal lineage determination.
Commitment of mesenchymal cells into the osteogenic lineage and
concurrent inhibition of myoblast differentiation into skeletal muscle
is a property of BMP-2 signaling. TGF-β1 also has potent effects on
mesenchymal cell differentiation and inhibits myogenesis (Katagiri et
al., 1994, 1997; Massague et al., 1986; Olson et al., 1986; Yamaguchi et
al., 1991). However, the question of how TGF-β signaling is
differentially interpreted in homogeneous mesenchymal cell popula-
tions that will eventually commit to different lineages is not clear.
Phosphorylation of Smad1/5 by the BMP-2 signaling cascade and
interaction with Runx2 activates expression of pro-osteogenic genes
such as OCN and ALP (Lee et al., 2000). TGF-β1 also potentiates BMP-
2-mediated conversion of mesenchymal cells into an osteogenic
phenotype through down-regulation of MRF protein expression and
inhibition of myogenesis (Lee et al., 2000). The TGF-β1-effector
Smad3 represses MyoD activity, although additional TGF-β1 effects
are also evident in muscle cells (Liu et al., 2001). Thus, co-ordination
of osteogenic and myogenic cell fates can be regulated by TGF-β1 and
BMP-2 signaling. Interestingly, interaction of R-Smads with various
other proteins such as Menin, confer the ability to modulate TGF-β1
and BMP-2 signaling in other cell types (Hendy et al., 2005; Kaji et al.,
2001; Sowa et al., 2003, 2004a,b).
The C2C12 and C3H10T1/2 cell lines have been used as models to
study the commitment of mesenchymal cells to the myogenic and
osteogenic lineages. In C2C12 and C3H10T1/2 cell lines, BMP-2
mediates inhibition of terminal differentiation of cells into skeletal
muscle and promotes an osteogenic phenotype (Katagiri et al., 1994,
1997). Previous reports implicate Menin, the protein product of the
Men1 gene, in the regulation of osteoblast differentiation in
C3H10T1/2 cells, based on its capacity to modulate BMP-2 signaling.
This effect is mediated by the interaction of Meninwith Smad 1/5 and
the key osteoblast transcription factor, Runx2 (Hendy et al., 2005;
Sowa et al., 2003, 2004a). In osteoblasts, interaction of Menin with
BMP-2 regulated Smads (Smad 1/5) is lost as committed osteoblasts
differentiate further and Menin then interacts with Smad3 to
negatively regulate Runx2 activity by TGF-β1 signaling (Sowa et al.,
2004a). Furthermore, a previous report documented a role for Menin
in osteogenic differentiation of Pax3-derived lineages as determined
by Pax3-Cre driven deletion of Menin leading to defects in palatogen-
esis and rib formation (Engleka et al., 2007). Inactivation of Menin
also blocks TGF-β1 signaling in anterior pituitary and parathyroid
cells, reducing their growth inhibition by TGF-β1 (Hendy et al., 2005;
Kaji et al., 2001; Sowa et al., 2004b). Interestingly, TGF-β1 and BMP-2
potently repress muscle cell differentiation although the role of Menin
in modulating myogenesis has not so far been reported.
Men1was ﬁrst studied as a tumor suppressor gene, responsible for
an autosomal dominant cancer syndrome, Multiple Endocrine
Neoplasia type 1 (MEN1) which is characterised by multiple tumors
of the parathyroid, endocrine pancreas, anterior pituitary and foregut-
derived neuroendocrine tissues (Agarwal et al., 2004; Poisson et al.,
2003). Menin is evolutionary conserved in various multi-cellular
organisms including mouse (Stewart et al., 1998), rat, zebraﬁsh(Khodaei et al., 1999) and Drosophila (Guru et al., 2001) with no
known homologue in the yeast, Saccharomyces cerevisae (Poisson et
al., 2003). Although the initial characterisation of Menin in MEN1
disease suggests a role as a tumor suppressor several roles have
subsequently been postulated including a central role in transcrip-
tional regulation, cell cycle control, apoptosis, genomic stability and
differentiation. Such diverse functions are facilitated by a variety of
interactions with cellular proteins such as: JunD, Smad3, MLL, Pem,
Nm23, NF-κB, RPA2, and nmMHCIIa (Karnik et al., 2005; MacConaill et
al., 2006; Milne et al., 2005; Poisson et al., 2003).
In mice,Men1 transcript is detected during early development and
is found in both non-endocrine and endocrine tissues as early as
embryonic day 7 (E7). At a later gestational stage (E17), Men1
expression is more restricted, with expression mainly conﬁned to the
thymus, skeletal muscle, brain and spinal cord. In contrast, analysis of
adult mouse tissue reveals an absence of Men1 transcript expression
in skeletal muscle although it is present in numerous other tissues
(Stewart et al., 1998). Interestingly, homozygous Men1 null-mice die
in utero between E11.5 and E13.5, and display delayed development
with defects in multiple organs, including the neural tube, heart, liver,
and cranial and facial formation (Crabtree et al., 2001). These
disparate effects do not seem to be attributable to a general cell-
autonomous effect. Therefore, a critical function for Menin has been
proposed during development, in addition to its role in MEN1 disease
(Crabtree et al., 2001; Sowa et al., 2003; Stewart et al., 1998).
In this report we document that reduction of Menin in mesench-
ymal cells leads to a precocious enhancement of differentiation into
skeletal muscle and conversely reduces osteogenic differentiation.
Menin directly potentiates Smad3 function and suppression of Menin
expression antagonizes TGF-β1 and BMP-2 mediated osteogenesis
and promotes myogenesis. Thus, we propose that Menin serves as a
molecular rheostat, functioning to balance the ratio of commitment of
mesenchymal cells to the myogenic and osteogenic lineages.
Materials and methods
Antibodies and reagents
The primary antibodies used for this study include: monoclonal
and polyclonal antibodies purchased from Santa Cruz; α-Menin (C-
19), α-GFP (B-2), α-dsRed (C-20), α-Myf-5 (C-20), α-MyoD (C-20),
α-c-Jun (H-79), α-Actin (I-19), and α-ERK 1 (C-16); polyclonal
antibody purchased from Bethyl Laboratories; α-Menin (BL-342);
monoclonal antibodies purchased from BD Biosciences; α-MEF2D
(610775), and α-Smad 2/3 (610842); monoclonal antibody pur-
chased from Abcam; α-GAPDH (ab8245); polyclonal antibodies
purchased from Cell Signaling Technology; α-p-Smad2 (3101), and
α-p-Smad3 (9514); monoclonal antibodies purchased from Develop-
mental Studies Hybridoma Bank; α-myogenin (F5D), and α-MyHC
(MF20); monoclonal antibody purchased from Sigma; α-Flag (M2);
monoclonal antibody purchased from R&D Systems; α-TGF-β1
(MAB1835). Polyclonal antibodyα-MEF2Awas prepared as previously
described (Cox et al., 2003). Normal mouse (sc-2025) and goat (sc-
2028) IgGs were purchased from Santa Cruz. Recombinant human
BMP-2 (355-BEC) and TGF-β1 (240-B) were purchased from R&D
Systems. Puromycin, MG132, CHX, and SIS3 were purchased from
Sigma for use in cell culture. All other reagents were obtained as
indicated herein.
Cell culture
Mouse C2C12 myoblasts and C3H10T1/2 embryonic ﬁbroblasts
were purchased from American Type Culture Collection (CLR-1772,
CCL-226) and maintained in growth medium (GM) consisting of 10%
FBS (HyClone) in high-glucose DME (Gibco) supplemented with 1%
penicillin–streptomycin (Gibco) in a humidiﬁed environment at 37 °C
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myotubes was induced by replacing GM with differentiation medium
(DM) which consisted of 2–5% horse serum (Atlanta Biologicals) in
DME supplemented with 1% penicillin–streptomycin. Cells were
monitored daily in all experiments for appropriate morphology.
Primary myoblast isolation
Primary mouse myoblasts were isolated from the hindlimbs of
1 day old neonatal mice. Brieﬂy, mice were sacriﬁced by decapitation
and the hindlimbs were rinsed with 70% ethanol before dissecting
skeletal muscle away from skin and bone. The muscle was kept moist
by soaking in PBS while mincing tissue with razor blades. Cells were
then dissociated by diluting the cell slurry twofoldwith a collagenase/
dispase/CaCl2 solution (1.5U/ml collagenaseD(BoehringerMannheim),
2.4 U/ml dispase II (Boehringer Mannheim), 2.5 mM CaCl2) followed
by continued mincing for three more minutes. To completely
dissociate cells, the slurry was incubated at 37 °C for 20 min with
intermittent trituration. Dissociated cells were then collected by
centrifugation for 5 min at 350 ×g and the cell pellet was resuspended
in 2–4 ml of F-10-based primary myoblast growth medium (20% FBS
(HyClone), 2.5 ng/ml bFGF (human; Promega), 1% penicillin–strepto-
mycin (Gibco)), before plating cells on a gelatin coated cell culture
dish. Myoblasts were enriched from the mixed population culture by
preplating cells for 15 min before passaging for four generations after
which cells were maintained in F-10/DMEM-based primary myoblast
growth media.
RNA extraction and Northern blot analysis
Total cellular RNAwas isolated with Trizol® (Invitrogen) according
to themanufacturer's instructions. RNAwas further puriﬁed for mRNA
by poly A isolation using a commercially purchased kit (Sigma,
S1560S). Brieﬂy, 2.5 μg of mRNA was resolved on agarose-formalde-
hyde gels andmRNAwas transferred onto Hybond-N plus membranes
(Amersham) by capillary transfer. Membranes were processed in
Perfect Hyb (Sigma) according to manufacturer's instructions and
hybridized with 32P-labeled cDNA probes overnight at 42 °C. Probes
were prepared as follows, the full length Menin ORF, full length
Myogenin ORF, and a 316 bp fragment of GAPDH (excised from pTRI-
GAPDH), were used to label probes for menin, myogenin, and GAPDH
detection. The probes were labeled with 32P using a DNA random
primer labeling kit (Sigma, N1500S) and puriﬁed on ProbeQuant™ G-
25 Columns (Amersham). After washing, membranes were exposed to
BioMax MR ﬁlm (Kodak). Between probing blots formenin,myogenin,
and GAPDH, blots were stripped with boiling water containing 0.1%
SDS and incubated with mild shaking at ambient temperature for
30 min.
Culture fractionation
Mononucleated cells and myotubes were fractioned from C2C12
cell cultures after being kept in DM for 4 days. It had previously been
reported that myotubes are more sensitive to detachment by
trypsinization than the mononucleated cells that are found in
differentiated C2C12 cell cultures (Kitzmann et al., 1998b). Brieﬂy,
cells were washed with PBS and then treated with a 0.13% Trypsin
solution in Versene for 1 min before removal of detached cells and
Trypsin solution. Residual cells remaining on the plate were then
removed by an additional treatment with the diluted Trypsin solution
for another minute. Cell extracts were prepared as described below.
Plasmids
Expression construct pcDNA3-Menin was obtained from Andre
Bedard (McMaster University, Canada). Expression constructs forpCMV5B-dominant-negative TGF-β receptor II (TβRII [K227R]), and
pCMV5B-Flag-Smad3 were gifts from J. Wrana (University of Toronto,
Canada). MRF expression plasmids were constructed in pEMSV as
described elsewhere (Davis et al., 1987). Transcription reporter
constructs p4R SV40-Luc (Perry et al., 2001), p3TP-Lux (Wrana et
al., 1992) and pCMV β-galactosidase are described elsewhere (Kollias
et al., 2006). The reporter construct pMyoD-Luc was a kind gift from
David J. Goldhamer (University of Pennsylvania). The reporter
construct pMCK-EGFP was a gift from A. Ferrer-Martinez (Universitat
de Barcelona, Spain). The pdsRed2-N1 expression construct was
purchased from Clontech Laboratories. pTRI-GAPDH was purchased
was purchased from Ambion. Small interfering RNA expression vector,
pSilencer 3.1-H1 puro (Ambion) containing four different Menin
targeting sequences and appropriate scrambled controls were con-
structed as per manufacturer's instructions. The siRNA targets which
were assayed for reduction of Menin expression included; 5′-
AAGGTCTCGGATGTCATATGG-3′ (Exon 1, si-1); 5′-AATTGCCTCAGC-
TAAGACCTA-3′ (Exon 5/6, si-2); 5′-AAGGAATTCTTTGAAGTGGCC-3′
(Exon 7, si-3); 5′-AATGCACATAGTTAGCCGG-3′ (Exon 10, si-4).
Protein extraction and immunoblotting
Cell extracts were prepared in NP-40 lysis buffer (0.1% NP-40,
150 mMNaCl, 1 mM EDTA, 50mM Tris pH 8.0, 1 mM sodiumvanadate,
1 mM PMSF, supplemented with a protease inhibitor cocktail (Sigma,
P-8340)) and protein concentrations were determined by Bradford
assay (BioRad). Nuclear and cytoplasmic protein extracts were
prepared using the NE-PER® nuclear and cytoplasmic extraction kit
(Pierce). Equivalent amounts of protein (10–30 μg) were electro-
phoretically resolved by SDS-PAGE on 6–10% gels, followed by
electrophoretic transfer to an Immobilon-P membrane (Millipore) as
directed by manufacturer. Blots were processed and incubated with
primary antibodies, α-Menin (1:500), α-GFP (1:2000), α-Actin
(1:2000), α-dsRed (1:2000), α-GAPDH (1:5000), α-p-Smad2
(1:2000), α-p-Smad3 (1:2000), α-Smad3 (1:1000), α-Myf-5
(1:1000), α-MyoD (1:1000), α-MEF2D (1:2000), α-MEF2A
(1:1000), α-Flag (1 μg/ml), α-c-Jun (1:2000), α-ERK 1 (1:1000), α-
Myogenin (1:5), or α-MyHC (1:5) in 5% milk in PBS or TBST or 5% BSA
in TBST as directed by manufacturer. Appropriate HRP-conjugated
secondary antibody was diluted (1:1000–1:5000) in 5% milk in PBS.
Enhanced chemiluminescence reagent (Amersham) was used to
detect secondary antibody bound to the membrane by exposure to
Biomax ﬁlm (Kodak).
Transfection
Lipofectamine® transfections were optimized as directed by
manufacturer. Brieﬂy, 8.0×104 cells per well were plated 1 d before
transfection in 6-well dishes. Lipofectamine®–DNA precipitates were
prepared using 8 μl Lipofectamine® and 2 μg total plasmid DNA per
well. Before addition of Lipofectamine®–DNA precipitate, cells were
washed twice in DME and then replaced with 0.8 ml DME. Cells were
incubatedwith DNA for 5 h before addition of complete growthmedia.
Twenty-four hours post-transfection cells were manipulated as
indicated for each experiment. Calcium phosphate–DNA precipitation
transfections were also carried out and cells were processed 16 h post-
transfection as indicated.
Microscopy and ﬂuorescence
Fluorescent and phase contrast pictures were obtained at RT
using an epiﬂuoresence microscope (Axiovert 35; Carl Zeiss
MicroImaging), with appropriate phase and ﬁlter settings, and a
10× NA 0.25 Achrostigmat objective lens. Images were digitized with
a camera (Canon, EOS D60) and acquired with EOS D60 software
(Canon).
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RT-PCR of 1 μg of total cellular RNA from C2C12 cells was
performed using the SuperScript III ﬁrst strand synthesis system for
RT-PCR (Invitrogen). PCR reactions were performed using forward
primer and reverse primers targeting Menin, F-5′-GCCGAGGCTGAA-
GAACCAT-3′, R-5′-TGCCGCTTTAGGAAAGAGAGT-3′ (28 cycles, 63 °C,
470 bp); GAPDH, F-5′-TTCACCACCATGGAGAAGGC-3′, R-5′-GGCATG-
GACTGTGGTCATGA-3′ (25 cycles, 61 °C, 250 bp); MCK, F-5′-AGGT-
CACCCCTTCATCATGAC-3′, R-5′-ACAGCTTCTCCACTGCACG-3′ (25
cycles, 61 °C, 281 bp); Myogenin, F-5′-TTTCTACCAGGAGCCCCACTT-
3′, R-5′-TGATGGCTTTTGACACCAAC-3′ (25 cycles, 63 °C, 707 bp). PCR
products were resolved on Agarose gels and stained with ethidium
bromide prior to imaging.
Sacromeric myosin heavy chain detection
C2C12 and C3H10T1/2 cells were examined immunohistochemi-
cally for MyHC expression. Brieﬂy, cells were washed in PBS and ﬁxed
with 90% methanol at −20 °C for 10 min. After ﬁxation cells were
incubated in 5% milk in PBS for 30 min at 37 °C to block non-speciﬁc
binding of antibodies. Cells were incubated at RT with primary
antibody α-MF-20 (1:20) diluted in blocking buffer for 1 h. Washed
three times with PBS and incubated for 60 min at RT with an HRP-
conjugated α-mouse antibody (1:2000). The cells were again washed
three times with PBS and incubated in developer (0.6 mg/ml DAB,
0.1% H2O2 in PBS) to detect bound HRP.
Luciferase assay
Transient transfections of C2C12 myoblasts and C3H10T1/2
ﬁbroblasts were performed using standard calcium phosphate–DNA
precipitation with pCMV-β-galactosidase serving as an internal
control of transfection efﬁciency. Transcription reporter assay
constructs and expression plasmids were transfected where indi-
cated in ﬁgures. Brieﬂy, 16 h following transfection, the cells were
washed with PBS and allowed to recover for 12 h in GM. Cells were
incubated for indicated times and conditions before cellular extracts
were prepared to determine luciferase activity using a luminometer
(Berthold Lumat, 9501) and Luciferase substrate (Promega) as
directed by manufacturer.
Co-immunoprecipitation assay
Equal protein amounts (500 μg) were diluted with NP-40 lysis
buffer to a ﬁnal concentration of 1 μg/μl. Protein complexes were
immunoprecipitated with 4.9 μgα-Flagmonoclonal antibody or 4.9 μg
normal mouse IgG, and 25 μl protein G-Plus Sepharose beads (50%
slurry) (Santa Cruz) by incubation at 4 °C overnight on a nutating
platform. The beads were washed with three changes of NETN wash
buffer (0.1% NP-40,150mMNaCl,1 mM EDTA, and 50mMTris–HCl pH
8.0). Beads were boiled in sample buffer, and protein complexes were
resolved by SDS-PAGE and immunoblotted as described prior.
Alkaline phosphatase and myosin heavy chain double stain
C2C12 cells were assayed histochemically for alkaline phosphatase
activity and stained for MyHC as previously described (Katagiri et al.,
1997). Brieﬂy, cells were ﬁxed for 10 min with 3.7% formaldehyde at
RT. Cells were then processed for MyHC detection as described above
with the following exception, before developing bound HRP-con-
jugated secondary antibody, cells were incubated for 20 min with ALP
developer (0.1 mg/ml napthol AS-MX phosphate (Sigma), 0.5% N,N-
dimethylformamide, 2 mM MgCl2 and 0.6 mg/ml of fast blue BB salt
(Sigma), and 0.1 M Tris, pH 8.5) at RT. Cells were then washed three
times with PBS before HRP-conjugated secondary antibody wasdeveloped with a commercially available kit with AEC as the
chromogenic substrate (Sigma).
Genotyping
Mouse genotyping was performed by PCR as described previously
(Engleka et al., 2007). Mice containing the ﬂoxed menin allele were
kindly provided by Dr. Francis Collins (National Institute for Human
Genome Research) (Scacheri et al., 2004). R26R-LacZ mice were
obtained from Jackson Laboratories, Inc. All mice were maintained on
mixed genetic backgrounds. The institutional animal care and use
committee of the University of Pennsylvania approved all animal
protocols.
Histology
Embryos were ﬁxed in 2% paraformaldehyde and processed for
parafﬁn sections. Detailed histology protocols are available at http://
www.med.upenn.edu/mcrc/histology core.
Statistics
To quantify number of muscle ﬁbers, cross-sectional ﬁbers were
counted using Grid_cell counter software. Statistical signiﬁcance of
mean values was determined by a 2-tailed Student's t test.
Results
Menin is down-regulated during myogenic differentiation
In mice, Men1 transcript is detected during embryonic develop-
ment and is expressed in numerous tissues including skeletal muscle.
Menin continues to be expressed in a variety of tissues postnatally, but
is down-regulated in skeletal muscle (Stewart et al., 1998). Further-
more,Men1 transcript levels increase in multipotent C3H10T1/2 cells
induced to differentiate into the osteogenic lineage by treatment with
BMP-2 (Sowa et al., 2003). We initially characterisedMen1 expression
in multipotent C2C12 and C3H10T1/2 mesenchymal cells induced to
differentiate into the skeletal muscle lineage to begin to determine the
role of Menin expression in this process.
Menin expression levels were determined by Northern and
Western analysis in C2C12 cells induced to differentiate into
myotubes. Fig. S1 A depicts Men1 transcript levels as relatively high
in actively proliferating myoblasts (MB, t=0), and progressively
diminishing as cells enter the myogenic program. Differentiation of
cells was monitored by muscle-speciﬁc Myogenin expression, and
GAPDH transcript levels were determined to monitor mRNA loading.
We analyzed Menin protein expression levels in C2C12 cells induced
to differentiate into skeletal muscle (Fig. S1 B). Western analysis
indicates that Menin protein level, in concert with mRNA expression
data, is reduced as cells undergo myogenic differentiation. Differ-
entiation of cells was determined by monitoring various muscle-
speciﬁc markers including MyHC, Myogenin, MEF2A and MEF2D.
Actin protein levels were assessed to monitor protein loading.
Differentiation of C2C12 cells into the myogenic lineage is a
stochastic process and a subpopulation of mononucleated cells
(reserve population) has previously been reported to retain an
undifferentiated, proliferative capacity even after induction of the
myogenic program in neighboring cells. Furthermore, the undiffer-
entiated cells retain higher expression levels of MRF transcription
factors, MyoD and Myf-5, while lacking expression of myogenic
markers such as Myogenin and MyHC (Kitzmann et al., 1998a). Given
our observation that Menin is still expressed at low levels in
differentiated C2C12 cells, we sought to address if there might be a
discordance of Menin expression in the two subpopulations found in
C2C12 cells induced to differentiate into the myogenic lineage. To
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(MT(e-enriched)) or mononucleated cells (MB(r-reserve)) and
performed Western analysis. Fig. 1A depicts that Menin is highly
expressed in the undifferentiated MB(r) fraction compared to the MT
(e) fraction. Moreover, the expression pattern of Menin parallels thatFig. 1.Menin is down-regulated during myogenic differentiation. (A) C2C12 cells at 80%
conﬂuency were harvested as myoblasts (MB), or switched to DM for 4 d before
harvesting whole cell populations (MT), fractionated mononucleated cells (MB(r)), or
fractionated myotubes (MT(e)) for Western analysis. Menin protein levels were
assessed as well as several myogenic markers and Actin to monitor muscle
differentiation and loading respectively. (B, C) C3H10T1/2 ﬁbroblasts were transiently
transfected with either pEMSV (Control) or pEMSV-MyoD (MyoD), and pCMV-dsRed2
as a marker of relative transfection efﬁciency and pMCK-EGFP to monitor conversion of
ﬁbroblasts into myogenic cells. Equivalently transfected cells were switched to DM at
80% conﬂuency for 3 d before harvesting to determine Menin protein levels byWestern
analysis. (C) Expression of variousmyogenic markers and Actinwas assessed tomonitor
muscle differentiation and protein loading respectively. ⁎, background band.of Myf-5 and is inversely related to Myogenin and MyHC expression.
Therefore, these data suggest that Menin expression is down-
regulated in differentiating cells and maintained in the undifferen-
tiated population.
The C3H10T1/2 multipotent mouse ﬁbroblast cell line undergoes
myogenic differentiation in a conversion assay when transfected with
MyoD. Myogenesis may be monitored using a muscle-speciﬁc Muscle
Creatine Kinase-EGFP reporter gene (MCK-EGFP) and morphological
myotube formation (Fig. 1B). Relative transfection efﬁciencies were
monitored by co-transfection of a constitutively active gene expres-
sing dsRed2 (CMV-dsRed2). Fig. 1C depictsWestern analysis of MyoD-
converted C3H10T1/2 cells maintained for 3 d in differentiation
conditions. Menin protein levels are reduced in cells expressing MyoD
as compared to control transfected cells. Various other markers of
myogenesis were also assessed to further characterise muscle
differentiation including MCK-EGFP, Myogenin, and MyHC. Actin
protein levels were assessed to monitor protein loading. Taken
together, these data indicate that Menin expression levels are reduced
as mesenchymal cells differentiate into skeletal muscle.
Reduced Menin expression leads to precocious differentiation of
multipotent mesenchymal and primary myoblast cells into skeletal
muscle
Given that Menin is expressed in myoblasts and down-regulated
during mesenchymal cell differentiation into skeletal muscle, we
hypothesized that premature suppression of Menin expression might
lead to precocious differentiation of C2C12 and C3H10T1/2 cell lines
into a skeletal muscle phenotype. To reduce Menin expression, four
siRNA constructs and corresponding scrambled siRNA's were designed
and cloned into pSilencer 3.1. The pSilencer 3.1 vector contains a
puromycin resistance gene and in experiments where it was
transfected into cells, all untransfected cells were killed by treatment
of cultures with a dose of puromycin which was sufﬁcient to kill all
cells in an untransfected control plate. Menin expressionwas reduced
for two of the four siRNA constructs targeting Menin (hereafter
referred to as siMenin-1 and -2) when compared to control
transfected cells. Results presented were observed using both siRNA
constructs and subsequent data is shown for si-1 (for si-2 data see
Fig. S2). As determined by semi-quantitative RT-PCR and Western
analysis, Fig. 2A depicts that Menin mRNA and protein levels were
reduced in cells expressing siMenin as compared to expression levels
in cells expressing a non-speciﬁc scrambled siRNA sequence (Con-
trol). GAPDH and ERK 1/2 levels were determined to monitor DNA
and protein loading respectively.
To analyze phenotypic effects resulting from reduction of Menin
expression on muscle differentiation, either the siMenin or control
siRNA constructs, were co-transfected with MCK-EGFP to monitor
myogenesis and CMV-dsRed2 to monitor relative transfection efﬁ-
ciencies. Fig. 2B depicts that cells with reduced Menin expression
(siMenin) displayed precocious myotube formation as compared to
control transfected cells. Differentiation of cells was monitored by
MCK-EGFP and immunostaining for MyHC (Fig. 2B), and both markers
indicate precociousmyogenesis whenMenin expression is attenuated.
Biochemical conﬁrmation of this observation was also carried out by
Western analysis (Fig. 2C) for various markers of myogenesis
including, Myogenin, MyHC, and MCK-EGFP. Actin levels were
determined to monitor protein loading and dsRed2 levels were
again used to monitor relative transfection efﬁciencies. Furthermore,
we assessed whether reduction of Menin expression in primary
mouse myoblasts could phenocopy the enhancement of myogenic
differentiation seen in C2C12 cells. As is normal with primary
myogenic cells, we were unable to achieve high levels of transfection
efﬁciency, therefore selection with puromycin was not undertaken in
these experiments. Thus, althoughwe observed a consistent enhance-
ment of skeletal muscle differentiation in cells with reduced Menin
Fig. 2. Reduced Menin expression in myoblasts leads to precocious differentiation. C2C12 cells were transiently co-transfected with pCMV-dsRed2, pMCK-EGFP, and either pSilencer-Control or pSilencer-siMenin. Transfected cells were
selected with puromycin (4 μg/ml) for 1 d before recovery in GM for 12 h. Upon recovery cells were switched to either GM or DM for times indicated before harvesting or ﬁxing cells to assess RNA and protein expression. (A) C2C12 cells were
maintained in GM 12 h post-recovery before harvesting cells for RNA or protein. RT-PCR indicates Menin transcript levels in cells transfected with siRNA as compared to control transfected cells; GAPDH levels were determined to monitor
loading. Western analysis of similarly transfected cells; ERK 1/2 levels were determined to monitor loading. (B) C2C12 cells were transfected and cultured for 4 d in DM as described above. Relative transfection efﬁciencies were monitored by
dsRed2 protein ﬂuorescence (after 1 d) and myogenesis monitored with MCK-EGFP signal. After taking ﬂuorescence pictures, cells were also ﬁxed and immunostained for MyHC (brown) detection and nuclei were counterstained with
haematoxylin (purple). Twelve random ﬁelds were counted for the number ofMyHC positive syncitia and themean plotted, error bars are representative of standard error of themean (SEM), n=12. (C) Transfected cells were incubated for 4 d
in DM before harvesting for protein. Expression of various myogenic factors and Actin were determined by Western analysis to monitor muscle differentiation and protein loading respectively. The graph is representative of 3 separate
experiments. (D, E) Primary mouse myoblasts were transiently co-transfected with pCMV-dsRed2, pMCK-EGFP, and either pSilencer-Control or pSilencer-siMenin. Transfected cells were allowed to recover for 24 h in GM and then switched to
DM for an additional 4 d before taking ﬂuorescence pictures, ﬁxing for MyHC detection, or harvesting cells to assess myogenesis by Western analysis. (D) Relative transfection efﬁciencies were monitored by dsRed2 protein ﬂuorescence and
myogenesis monitored with MCK-EGFP (data not shown). Cells were also immunostained for MyHC (brown) detection and nuclei were counterstained with haematoxylin (l. blue). Eight random ﬁelds were counted for the number of MyHC
positive syncitia and the mean plotted, error bars are representative of standard error of the mean (SEM), n=8. (E) Expression of MCK-EGFP, dsRed2, and Actin was determined to monitor muscle differentiation, relative transfection
efﬁciencies, and protein loading, respectively. 121
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122 A. Aziz et al. / Developmental Biology 332 (2009) 116–130expression (Figs. 2D, E), the effect was lesser in primary myoblasts
compared to the clonal C2C12 cell line because of the lack of
enrichment for transfected cells. These data suggest that endogenous
expression of Menin in multipotent mesenchymal cells normally
represses myogenic differentiation and that reduction of Menin
expression enhances myogenesis.
We next determined if Menin suppression could enhance MyoD's
capacity for myogenic conversion in multipotent C3H10T1/2 cells. In
agreement with the phenotypic observations made with C2C12 cells,
C3H10T1/2 cells expressing the siMenin construct exhibited con-
siderably augmentedmyogenic conversion byMyoD as determined by
MCK-EGFP and MyHC detection (Fig. 3A). Western analysis was
performed (Fig. 3C) for various markers of myogenesis and these data
conﬁrmmorphological observations. Taken together, our observations
indicate that, in either C2C12, primary myoblast, or C3H10T1/2 cells
induced to differentiate into skeletal muscle, molecular genetic
reduction of Menin leads to precocious and enhanced myogenic
differentiation.Fig. 3. Reduced Menin expression results in precocious differentiation of C3H10T1/2 cells tr
dsRed2, pMCK-EGFP, and either pSilencer-Control or pSilencer-siMenin. Transfected cells w
recovery cells were switched to DM for times indicated before analysis. (A) C3H10T1/2 cell
efﬁciencies were monitored by dsRed2 protein ﬂuorescence and myogenesis monitore
immunostained for MyHC (brown) detection and nuclei were counterstained with haemat
syncitia and the mean plotted, error bars are representative of SEM, n=12. (B) Similarly tra
various myogenic factors and Actinwas determined byWestern analysis to monitor muscle d
experiments.Ectopic Menin expression reduces MyoD-induced skeletal muscle
conversion in C3H10T1/2 cells
Since Menin is down-regulated in myogenic cells and loss-of-
function leads to precocious muscle differentiation, we next per-
formed a gain-of-function assay to determine the effect that
constitutive maintenance of Menin expression might have on
myogenesis. C3H10T1/2 cells expressing MyoD, or transfected with
empty vector (Control) were co-transfected with an expression
construct for Menin or its corresponding empty vector, and cells
were induced to differentiate into skeletal muscle. As previously
described, gene constructs expressing CMV-dsRed2 and MCK-EGFP
were co-transfected. Fig. 4A depicts reduced numbers of MCK-EGFP
positive cells when MyoD and Menin expression constructs were co-
transfected as compared to cells transfected with MyoD alone. A
reduction in the degree of muscle differentiation was also noted by
MyHC immunostaining in cells with ectopic Menin expression, which
is consistent with observations made with an MCK-EGFP reporteransfected with MyoD. C3H10T1/2 cells were co-transfected with pEMSV-MyoD, pCMV-
ere selected with puromycin (4 μg/ml) for 1 d before recovery in GM for 12 h. Upon
s were transfected and cultured for 3 d in DM as described above. Relative transfection
d with MCK-EGFP signal. After taking ﬂuorescence pictures, cells were ﬁxed and
oxylin (purple). Twelve random ﬁelds were counted for the number of MyHC positive
nsfected cells were incubated for 3 d in DM before harvesting for protein. Expression of
ifferentiation and protein loading respectively. The graph is representative of 3 separate
Fig. 4. Ectopic Menin expression reduces the potency of MyoD-induced muscle conversion in C3H10T1/2 cells. C3H10T1/2 cells were transiently co-transfected with pEMSV
(Control) or pEMSV-MyoD (MyoD) and pCMV-dsRed2, pMCK-EGFP, and either pcDNA3 or pcDNA3-Menin. Transfected cells were allowed to recover in GM for 12 h before switching
to DM for 2 days. (A) Transfection efﬁciencies were monitored by dsRed2 protein ﬂuorescence and myogenesis monitored with MCK-EGFP signal. After taking ﬂuorescence pictures,
cells were ﬁxed and immunostained for MyHC (brown) detection and nuclei were counterstained with haematoxylin (purple). Twelve random ﬁelds were counted for the number of
MyHC positive syncitia and the mean plotted, error bars are representative of standard error of the mean (SEM), n=10. (B) Expression of various myogenic factors and Actin was
determined by Western analysis to monitor muscle differentiation and protein loading respectively. The graph is representative of 3 separate experiments.
123A. Aziz et al. / Developmental Biology 332 (2009) 116–130gene (Fig. 4A). Western analysis corroborated these observations (Fig.
4C). Interestingly, when we analyzed MyoD protein levels we noted
reduction of MyoD expression in cells ectopically expressing Menin
(Fig. 4C). To address whether this was due to an effect on MyoD
protein stability we repeated this experiment with the inclusion of
MG132 to inhibit proteosome-mediated degradation and cyclohex-imide (CHX) to inhibit de novo protein translation. Fig. S3 indicates
that inhibition of proteosome function and translational blockade
maintain MyoD protein levels in the presence of ectopically expressed
Menin as compared to control transfected cells. Therefore, the
reduction of MyoD levels in the presence of Menin is attributed to a
decrease in MyoD protein stability. These data indicate that
124 A. Aziz et al. / Developmental Biology 332 (2009) 116–130constitutive ectopic Menin expression reduces myogenic conversion
in C3H10T1/2 cells induced to differentiate into the myogenic lineage.
Menin is required for TGF-β1-mediated inhibition of myogenesis in
C2C12 cells
Since previous reports have implicated Menin in modulating
signaling of the TGF-β superfamily ligands, and also that TGF-β1 is
know to inhibit myogenesis, we postulated that Menin might impinge
on autocrine TGF-β1 signals (Hendy et al., 2005; Kaji et al., 2001;
Lacerte et al., 2004; Liu et al., 2001; Massague et al., 1986; Sowa et al.,
2003, 2004b). Consistent with an autocrine role for TGF-β1 in
repressing myogenesis, a TGF-β1 neutralizing antibody enhances
myogenesis (Fig. 5A). We next determined if reduction of MeninFig. 5. Reduction of Menin expression suppresses inhibition of myogenesis by TGF-β1. (A)
(1.0 ng/ml) with or without addition of TGF-β1 (1.0 μg/ml) neutralizing antibody (nTGF-β
counterstained with haematoxylin (purple). (B, C) C2C12 cells were transiently co-transfect
Transfected cells were selected with puromycin (4 μg/ml) for 1 d before recovery in GM for 12 h
to cells as indicated before ﬁxing or harvesting replicatewells for MyHC detection or RT-PCR ana
(data not shown) and myogenesis monitored with MCK-EGFP signal. After taking ﬂuorescen
counterstained with haematoxylin (purple). (C) Replicate wells were harvested for RNA and RT
loading respectively.expression levels could modify the inhibitory effect of TGF-β1 on
myogenic cells. Fig. 5B indicates that myogenesis was partially
restored by suppression of Menin expression when TGF-β1
(0.25 ng/ml–2 ng/ml tested, only 1.0 ng/ml data shown) was added
to cells that were induced to differentiate into skeletal muscle. MyHC
staining further conﬁrmed that myogenesis was rescued from
TGF-β1-mediated inhibition by reduction of Menin expression
(Fig. 5B). Using semi-quantitative RT-PCR, mRNA levels for markers of
myogenesis were determined and the data are congruent with the
phenotypic observations, in that higher levels of expression are seen
for MCK and Myogenin, in cells expressing the siMenin construct as
compared to control transfected cells in the presence of exogenously
added TGF-β1 (1.0 ng/ml). These data implicate Menin in enhancing
TGF-β1 signaling in muscle cells.C2C12 cells were cultured in DM for 3 d in the presence of exogenously added TGF-β1
1). Cells were ﬁxed and immunostained for MyHC (brown) detection and nuclei were
ed with pCMV-dsRed2, pMCK-EGFP, and either pSilencer-Control or pSilencer-siMenin.
. Upon recovery cells were switched to DM for 3 dwith the addition of TGF-β1 (1.0 ng/ml)
lysis. (B) Relative transfection efﬁciencies weremonitored by dsRed2 protein ﬂuorescence
ce pictures cells were ﬁxed and stained for MyHC (brown) detection and nuclei were
-PCR was performed formyogenin,MCK and GAPDH to monitor muscle differentiation and
Fig. 6. Menin potentiates TGF-β1-dependent reporter gene activation. (A) C2C12 cells
were transiently co-transfected with the TGF-β1 reporter gene p3TP-Lux, pCMV β-
Galactosidase to normalize transfection efﬁciencies and either pcDNA3 or pcDNA3-
Menin with or without pCMV5B (Control) or pCMV5B-dnTGFβIIR. Transfected cells
were allowed to recover for 12 h in GM before switching media to DM with either
diluent or TGF-β1 (1.0 ng/ml) added for 1 d before harvesting cells for Luciferase and β-
Galactosidase assays. SEM, n=3 (B) C2C12 cells were transiently co-transfected with
TGF-β1 reporter gene p3TP-Lux, pCMV β-Galactosidase to normalize transfection
efﬁciencies and either pSilencer-Control or pSilencer-siMenin. Transfected cells were
allowed to recover for 12 h in GM before switching media to DM with either diluent or
TGF-β1 (1.0 ng/ml) added for 1 d before harvesting cells for Luciferase and β-
Galactosidase assays. Bars represent fold activation of reporter gene 3TP-Lux in TGF-β1
treated cells over equivalently transfected diluent treated cells. SEM, n=3. The graphs
are representative of 3 separate experiments.
125A. Aziz et al. / Developmental Biology 332 (2009) 116–130Since reduction of Menin expression reduced the efﬁcacy of TGF-
β1-mediated inhibition of myogenesis, we next sought to determine if
Menin could modulate transcriptional activation of TGF-β1-regulated
gene expression in a myogenic context. As shown in Fig. 6A, ectopic
Menin expression led to a pronounced increase in TGF-β1 respon-
siveness for a TGF-β1-responsive reporter gene, 3TP-Lux, as compared
to control transfected cells. C2C12 cells were also co-transfected with
an expression construct for a dominant-negative version of TGF-βRIIFig. 7. TGF-β1-dependent reporter gene activation by Menin is inhibited by SIS3. C2C12 c
Galactosidase to normalize transfection efﬁciencies and either pcDNA3 or pcDNA3-Menin. T
with either diluent or TGF-β1 (1.0 ng/ml) and SIS3 (at indicated amounts) added for 1 d be
representative of 3 separate experiments.(dnTGF-βRII) which remains in a hypophosphorylated state and is
thus unable to phosphorylate Smad proteins and activate 3TP-Lux.
Further supporting a role for modulation of TGF-β1-signaling by
Menin, co-transfection of dnTGF-βRII and Menin expression con-
structs led to reduced activation of 3TP-Lux whether TGF-β1 was
present or not. Conversely, Fig. 6B depicts a reduced activation of 3TP-
Lux by TGF-β1 in cells with reducedMenin levels. We also assayed the
ability of Menin to modulate myogenic reporters MyoD-Luc and 4R
SV40-Luc and did not observe any changes in expression of these
reporter genes (data not shown). Taken together these data suggest
that TGF-β1-mediated inhibition of myogenesis requires Menin and
that Menin is able to modulate transcriptional activation of Smad
dependent, but not muscle-speciﬁc, target genes by TGF-β1 signaling.
Menin physically and functionally interacts with Smad3 in
myogenic cells
Having observed that Menin expression modulates TGF-β1
signaling in muscle cells, we hypothesized that Menin might intersect
with downstream effectors of TGF-β1 signaling. Since it has been
reported that Smad3 is the recipient of TGF-β1 signaling mediating
the inhibition of myogenesis, we assessed whether the potentiation of
TGF-β1 signaling by Meninwas through regulation of Smad3 function
(Liu et al., 2001). We utilized a speciﬁc inhibitor of Smad3
phosphorylation (SIS3), as it had previously been reported to inhibit
Smad3 phosphorylation and function but not of Smad2. To determine
the minimal amount of SIS3 required to inhibit Smad3 phosphoryla-
tion we carried out a dose response experiment and determined that
5 μM was sufﬁcient to inhibit TGF-β1 mediated phosphorylation of
Smad3. Western analysis (data not shown) was used to assess the
phosphorylation status of Smad2 and Smad3 in response to SIS3. In
agreement with previous reports, treatment of cells with 5 μM of SIS3
overnight attenuated phosphorylation of Smad3 but not of Smad2
(Jinnin et al., 2006). We next tested the ability of SIS3 to repress
activation of reporter gene, 3TP-Lux, by TGF-β1. Fig. S4 indicates that
inclusion of SIS3 was able to repress activation of the TGF-β1-
responsive reporter gene. These data indicate that the TGF-β1-
responsive reporter gene, 3TP-Lux is activated by phosphorylated
Smad3 and not Smad2 which remains phosphorylated in the presence
of TGF-β1 and SIS3. We next repeated the aforementioned reporter
gene assays with Menin overexpression and observed that activation
of Smad3-dependendent reporter gene activity was attenuated in the
presence of SIS3 (Fig. 7). Thus, these data indicate that potentiation of
the TGF-β1-responsive reporter genes by Menin is by potentiation of
Smad3 transcriptional activity.
We have previously observed that Smad3 localization is regulated
in muscle cells by TGF-β1 signaling (Quinn et al., 2001). Previousells were transiently co-transfected with a TGF-β1 reporter gene p3TP-Lux, pCMV β-
ransfected cells were allowed to recover for 12 h in GM before switching media to DM
fore harvesting cells for Luciferase and β-Galactosidase assays. SEM, n=3. The graph is
126 A. Aziz et al. / Developmental Biology 332 (2009) 116–130reports have also suggested that Menin may be localized in either the
cytoplasm or the nucleus (Huang et al., 1999). We therefore assessed
the subcellular localization of Menin and Smad3 in muscle cells.
C2C12 cells were fractioned into whole, cytoplasmic, or nuclear
extracts, either as myoblasts (t=0) or after treatment with TGF-β1
(1.0 ng/ml) or diluent for 12 h in differentiation conditions. Western
blot analysis was undertaken on whole, cytoplasmic, or nuclear
extracts. As indicated in Fig. 8A, fractionation was successful, as
determined by detection of the nuclear localized c-Jun protein in the
nuclear fraction and the predominantly cytosolic detection of GAPDH.
Western blots for Menin and p-Smad3 depict both proteins as being
localized to the nucleus of C2C12 cells treated with TGF-β1. HavingFig. 8. Menin physically and functionally cooperates with Smad3 in myogenic cells and pote
(t=0) were harvested or switched to DM and treated with TGF-β1 as indicated before har
prepared and assayed byWestern analysis. (B) C2C12 cells were transiently co-transfected w
recover for 12 h in GM before switching media to DM with either diluent (data not shown) o
α-Flag andα-Menin antibodies. Blotswere probed forMenin. Input represents 5% or 20 μg of t
transfected with pEMSV-MyoD and pcDNA3 or pcDNA3-F-Smad3, pCMV-dsRed2, pMCK-EGF
siMenin (siRNA sequence targeting Menin, siMenin). Transfected cells were selected with pu
2 d before taking pictures. Relative transfection efﬁciencies were monitored by dsRed2 protobserved co-localization in the nucleus we next performed co-
immunoprecipitation analysis in C2C12 cells to test whether the two
proteins were able to physically interact in a myogenic context in the
presence of exogenously added TGF-β1 (1.0 ng/ml). Fig. 8B depicts
that Flag-Smad3 (F-Smad3) and Menin interact as indicated by co-
immunoprecipitation, conversely therewas a reduced interaction of F-
Smad3 andMeninwhen TGF-β1 was not added (data not shown). Cell
lysates were immunoprecipitated with IgG as a negative control and
no interaction was observed.
Given that Menin could physically and functionally interact with
Smad3 we next sought to address whether reduction of Menin
expression could rescue the inhibitory effect of ectopic Smad3ntiates TGF-β1 dependent reporter gene activation. (A) C2C12 cells at 80% conﬂuency
vesting. Protein extracts of whole (W), cytoplasmic (C), or nuclear (N) fractions were
ith pcDNA3 Menin and pCMV F-Smad3 (ﬂag tagged). Transfected cells were allowed to
r TGF-β1 (1.0 ng/ml) added for 1 d before harvesting for co-immunoprecipitation with
otal cell lysatewhichwas immunoprecipitated. (C) C3H10T1/2 cells were transiently co-
P, and either pSilencer-Control (scrambledMenin siRNA sequence, Control) or pSilencer-
romycin (4 μg/ml) for 1 d before recovery in GM for 12 h. Cells were incubated in DM for
ein ﬂuorescence and myogenesis monitored with MCK-EGFP signal.
Fig. 9. Reduction of Menin expression in BMP-2 converted C2C12 cells attenuates bone
formation and suppresses inhibition of myogenesis. (A) C2C12 cells were transfected
with either pSilencer-Control or pSilencer-siMenin. Transfected cells were selectedwith
puromycin (4 μg/ml) for 1 d before recovery in GM for 12 h. Upon recovery cells were
switched to DM and were cultured for 3 d with diluent (Control) or BMP-2 (100 ng/ml)
added. Cells were ﬁxed and double stained for MyHC (arrows, orange) and ALP (blue).
(B) Replicate wells were harvested for RNA and RT-PCR was performed for myogenin,
MCK and GAPDH to monitor muscle differentiation and loading respectively.
Fig.10. Tissue-speciﬁc deletionofMenin in somiteprecursors augments intercostalmuscle
mass. Saggital sections of theﬁrst intercostalmuscle from Pax3cre/+ ;meninloxP/loxP (−/−),
Pax3cre/+ ; meninloxP/+ (+/−), and wildtype (+/+) mice. Mice were sacriﬁced at birth
and tissue sections stained with haematoxylin and eosin before counting muscle ﬁbers. R,
rib; L, lung; I, intercostal muscle; [], denotes enlarged area. SEM, n=8.
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cells ectopically expressing MyoD and F-Smad3, muscle differentia-
tion was attenuated as indicated by MCK-EGFP compared to cells
transfected with MyoD alone (Fig. 8C). However, in cells also
expressing the siMenin construct, the inhibitory effect of Smad3 on
myogenic differentiation was reduced. In summary, several lines of
evidence support the idea that Menin potentiates the activity of
Smad3 to enhance TGF-β1 sensitivity in muscle cells.
Reduced Menin expression inhibits BMP-2 dependent conversion of
C2C12 cells into osteoblasts and promotes myogenesis
C2C12 cells terminally differentiate into muscle upon reduction of
mitogens in themedia. Thus, they are termedmyoblasts although they
are also able to trans-differentiate into other mesenchymal pheno-
types. Consistent with a role for Menin in the commitment of
mesenchymal cells to differentiate into various phenotypes, previous
studies have shown that reduction of Menin expression leads to
impaired bone formation (Crabtree et al., 2001; Sowa et al., 2003,
2004a). To determinewhether Meninmight play a role in the decision
of mesenchymal progenitors to differentiate into either myogenic or
osteogenic lineages, Menin expression was reduced in C2C12 cells by
siRNA and cells were treatedwith either diluent or BMP-2 (100 ng/ml)
and induced to differentiate into muscle before ﬁxing and double
staining cells for MyHC (to indicate myogenesis) and ALP (to indicate
osteogenesis) (Fig. 9A). Reduction of Menin expression levels in the
presence of BMP-2, led to a substantial reduction in the number of ALP
positive cells as compared to control transfected cells. Concomitantly,
cells treated with BMP-2 also had reciprocally more MyHC positive
cells whenMenin expressionwas reduced. Fig. 9B indicates thatmRNA
expression levels for MCK and myogenin are in agreement with the
phenotypic observations as higher levels of both markers are seen in
cells with reduced Menin levels. Thus, these data indicate that Menin
expression modulates the commitment of mesenchymal cells to the
myogenic or osteogenic lineages.Increased intercostal muscle mass caused by tissue-speciﬁc deletion
of Menin in somite precursors
Gene targeting in mice to inactivate the Men1 gene resulted in
defects in rib formation (Engleka et al., 2007). In these mice, Men1
excisionwas achieved using the Cre–Lox system by ﬂanking exons 3–8
at theMen1 locus with loxP sites and using a Pax3-driven Cre cassette
to excise the gene (Engleka et al., 2007). Since Pax3 is expressed in
sclerotomal and myotomal progenitors throughout the somite, Menin
knockout also occurred in skeletal muscle precursors as well as the
sclerotomal derived bone precursors. The musculature of these mice
was not analyzed although overt effects on muscle development were
not apparent by gross morphological assessment. Based on our
observation that Menin might modulate the balance of myogenic
and osteogenic precursors, we undertook an analysis of selected
muscles from the Menin conditional knockout mice. Our analysis
revealed subtle but repeatedly observed differences in the amount of
muscle produced in the intercostal muscles in Menin conditional
knockout mice compared to the wild type mice (Fig. 10, ﬁrst
intercostal muscle shown). We analyzed these muscles in particular
because they originate from the non-migratory compartment of the
somite and are derived from both the hypaxial and epaxial domains of
the somite (Kablar et al., 1998). Thus, as would be predicted based on
our in vitro observations the absence of Menin in somite precursors, in
vivo, alters the balance of cells entering the myogenic and osteogenic
lineages. These observations are consistent with Menin playing a
modulatory role in altering cellular competence to BMP-2 and TGF-β1
signaling.
Discussion
In this report we present a series of experiments documenting a
role for the tumor suppressor protein Menin as a pivotal regulator of
mesenchymal cell commitment into osteogenic or myogenic lineages.
Our observations support a role for Menin in promoting osteoblast
progression whilst limiting myogenic differentiation in mesenchymal
cells. First, endogenous Menin expression is reduced in mesenchymal
cell lines induced to differentiate into skeletal muscle while
constitutive expression impairs muscle differentiation. Second, reduc-
tion of Menin expression by siRNA in mesenchymal cells causes
precocious myogenic differentiation at the expense of osteogenic
lineage progression. Third, Menin markedly potentiates TGF-β1
signaling in mesenchymal cells which leads to inhibition of
Fig. 11.Menin expression level is correlated with mesenchymal cell commitment to the
myogenic or osteogenic lineages. (A) Menin potentiates BMP-2-induced Smad1/5
transcriptional activity and promotes osteogenesis. Menin also potentiates TGF-β1
mediated Smad3 repression of myogenesis in mesenchymal cells. (B) Menin expression
is upregulated inmesenchymal cells induced to differentiate into the osteogenic lineage
(blue). Conversely, Menin is down-regulated during mesenchymal cell commitment to
the myogenic lineage (red).
128 A. Aziz et al. / Developmental Biology 332 (2009) 116–130myogenesis due to a synergistic molecular interaction betweenMenin
and the TGF-β1 responsive Smad3 transcription factor. Finally in
support of these observations, lineage-speciﬁc inactivation of Menin
in muscle progenitor cells in the somite lead to a demonstrable
enhancement in the number of muscle ﬁbers in intercostal muscle
derived from the non-migratory hypaxial and epaxial precursors.
Therefore, we propose that Menin functions in mesenchymal cells to
modulate TGF-β1/BMP-2 signals to regulate the balance of commit-
ment into myogenic and osteoblast lineages, respectively. Thus, our
studies underscore a novel role for down-regulation of Menin
expression for differentiation of multipotent mesenchymal cells into
skeletal muscle.
Gene targeting experiments have been useful in the consideration
of Menin's in vivo function. Homozygous deletion of Menin invokes
embryonic lethality at E11.5–13.5 due to neural, craniofacial and heart
malformations (Crabtree et al., 2001). Recently, tissue-speciﬁc
inactivation of Menin in neural crest precursor cells was found to
impair palatogenesis, rib formation, and perinatal viability, which is
consistent with the idea that Menin can play a pro-differentiation role
in some tissue types that depend on mesenchymal cell commitment
and differentiation (Engleka et al., 2007). In this report we further
analyzed these mice and noted an increase in the number of muscle
ﬁbers in mice with inactivated Menin concurrent with the previously
reported rib abnormalities. This observation is also congruentwith the
documented role of Menin in osteoblast lineage progression in vitro,
wherein Meninwas reported to promote osteogenesis by potentiating
Smad1/5mediated gene transcription (Hendy et al., 2005; Sowa et al.,
2003, 2004a), and our data concerning its role in myogenesis. We did
not assay for differences in chondrogenic and adipogenic differentia-
tionwhenMenin expression levels were altered as it has already been
reported that Menin play a role in differentiation of these lineages
(Sowa et al., 2003).
Menin was ﬁrst studied as the tumor suppressor gene responsible
for MEN1 disease which is characterised by formation of tumors in
multiple endocrine organs (Agarwal et al., 2004; Poisson et al., 2003).
Since then numerous mechanisms have been suggested for the tumor
suppressor function of Menin including regulation of gene expression,
genome stability, cell cycle progression, and cytokinesis (Agarwal et
al., 2004; Karnik et al., 2005; MacConaill et al., 2006; Milne et al.,
2005). These disparate but critical functions for tumor suppression by
Menin have been attributed to its association with a variety of
interacting protein partners in neoplastic cells. We initially assessed
whether Menin was exerting an effect on myogenesis through
disregulation of the cell cycle by regulating p27 expression. There
was no change in expression of p27 in C2C12 cells with reducedMenin
expression as compared to control cells (data not shown). One
recurrent interacting partner for Menin is the Smad3 transcription
factor and this interaction has been reported to be required for various
TGF-β1-mediated effects such as cell growth inhibition (Kaji et al.,
2001), secretion of parathyroid hormone in cultured parathyroid cells
(Sowa et al., 2004b), and secretion of extracellular matrix proteins in
mouse embryonic ﬁbroblasts (Hendy et al., 2005; Ji et al., 2007). In
addition to modulation of TGF-β1 signaling in glandular cells, Menin
has also been shown to regulate TGF-β1 signaling in mesenchymal
cells committed to the osteogenic lineage. Interestingly, TGF-β1 is a
potent inhibitor of myogenesis and the mechanism of this effect has
been extensively studied. Early work implicated the mode of
inhibition by TGF-β1 signaling on myogenesis to be due to transcrip-
tional down-regulation of MyoD and myogenin gene expression (Liu
et al., 2001; Massague et al., 1986; Olson et al., 1986). More recent
studies have expanded on this idea, and propose that inhibition of
MRF gene expression by TGF-β1 is also mediated by physical
interaction of Smad3 and MyoD, which impairs MyoD function by
inhibiting activation of E-box dependent muscle-speciﬁc gene
expression (Liu et al., 2001). Other effects have also been attributed
to TGF-β1 signaling in myogenic cells including changes in celladhesion (Heino and Massague, 1990), crosstalk with the MEK/ERK
mediated receptor tyrosine kinase cascade (Pena et al., 2000), and
secretion of extracellular matrix proteins (Chan et al., 2007). Thus,
there is considerable molecular complexity in the response of
myogenic cells to TGF-β1 signals and an integrated understanding of
how these disparate molecular events conspire to inhibit myogenesis
is just beginning to be appreciated.
Here, we show that Menin directly interacts with and modulates
Smad3 transcriptional activity in muscle cells. We investigated two
possible consequences of this interaction; ﬁrst, that Menin enhances
Smad3-mediated inhibition of MRF activity; second, that Menin
potentiates Smad3-mediated gene expression to inhibit myogenesis.
To assess whether Menin is part of the reported MyoD:Smad3 protein
complex, we performed co-immunoprecipitation reactions for the
three proteins, and did not detect a ternary protein complex contain-
ing all three proteins. However, in myogenic cells we did detect an
interaction between Menin and Smad3, and interestingly the inter-
action was potentiated by TGF-β1 treatment. Moreover, we also
observed that Menin was able to activate the TGF-β1 responsive
reporter gene 3TP-Lux but not myogenic reporter genes, 4RTK-Luc or
MyoD-Luc. We therefore suggest a model for the function of Menin in
multipotent mesenchymal cells in which Menin is excluded from a
MyoD:Smad3 protein complex and thus does not regulate Smad3-
mediated repression of E-box-dependent gene expression. However,
Menin potently enhances the activity of Smad3 at TGF-β1 target genes
and therefore potentiates the inhibitory effect of TGF-β1 signals. Thus,
we are in agreement with previous reports that treatment of
myogenic cells with TGF-β1 results in down-regulation of MyoD
gene expression and activity by inhibition of E-box dependent gene
expression. However, we additionally propose that synergistic inter-
action between Smad3 and Menin potentiates TGF-β1-responsive
gene expression in myoblasts and this serves to inhibit myogenesis via
TGF-β1 signaling. These molecular events lead to a strong sustainable
inhibition of the myogenic differentiation program, but are also
reversible upon cessation of the TGF-β1 signal. Thus, Menin interac-
tion with Smad3 and its potentiation of TGF-β1 signaling is a potent
repressor complex that prevents precocious myogenesis in progenitor
cells.
Recently, data supporting a potential role of the Pitx2 transcription
factor in protecting muscle cells from osteoblast conversion has been
reported. The suggestion is that Pitx2 suppresses pro-osteogenic
signals induced by BMP-2 in myoblasts to prevent osteoblast
conversion (Hayashi et al., 2008). Similarly, we suggest that Menin
expression suppresses pro-myogenic signals in myoblasts to prevent
129A. Aziz et al. / Developmental Biology 332 (2009) 116–130muscle differentiation by potentiating BMP-2 and TGF-β1 signals.
Trans-differentiation of myoblasts and osteoblasts is a topic of
considerable interest since the precursor cells for both cell types
often lie in proximity to each other during development and in post-
natal life and these relatively unprogrammed cells are often exposed
to similar signaling environments. Moreover, inter-conversion from
muscle to bone has been reported in pathologic conditions such as
Myositis Ossiﬁcans Traumatica, in which muscle trauma leads to
ectopic de novo bone formation in skeletal muscle. Also, osteogenic
sarcoma can lead to formation of bone in skeletal muscle, suggesting
the potential for interconversion between the two lineages (Shafritz
and Kaplan, 1998). Interestingly, it has been reported that a single
BMP-2 injection induces endochondral ossiﬁcation of muscle tissue in
mouse quadriceps muscle (Clancy et al., 2003). In this regard,
determination of whether ectopic bone formation in muscle is
dependent on re-activation of Menin expression and concomitant
Pitx2 down-regulation will be of considerable interest.
Clearly, the complex circuitry of genes inducing, and also limiting,
the fate of multipotent mesenchymal stem cells is just beginning to be
unraveled and this knowledge is important in our understanding of
bone and muscle lineage commitment during ontogeny and pathol-
ogy. Based on our data we have constructed a testable model of the
role of Menin in myogenesis (Fig. 11). We propose that down-
regulation of Menin is a requirement for mesenchymal cell differ-
entiation into the myogenic lineage in order to abrogate autocrine
TGF-β1 signaling which serves to inhibit myogenesis through
regulation of Smad-responsive genes. Conversely, maintenance of
Menin expression potentiates pro-osteogenic Smad protein activity to
promote osteogenesis (Sowa et al., 2003, 2004a,b). In summary, the
tumor suppressor protein Menin, additionally functions in mesench-
ymal cells to regulate the balance of commitment into the myogenic
and osteogenic lineages.
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